Core Insights - Vivos Inc. has been granted U.S. Patent No. 12,521,452 B2 for its innovative cancer treatment technology, specifically a radioactive thermogel suspension that enhances its Precision Radionuclide TherapyTM platform [1][2] Patent and Technology - The patent protects a novel thermosensitive PLGA-g-PEG hydrogel combined with yttrium-90 particles, allowing for precise, localized radiation delivery to solid tumors while minimizing damage to healthy tissue [2] - The gel remains injectable at room temperature and solidifies at body temperature, ensuring effective immobilization of the radiation source [2] Intellectual Property Developments - Vivos has received approval for its PRECISIONGEL™ trademark in the U.S. and New Zealand, and has filed a new patent application to further protect its hydrogel technology [3] - The new application covers the hydrogel's use as a carrier for various therapeutic agents, reinforcing the company's position in advanced hydrogel-based delivery systems [3] Strategic Vision - The CEO of Vivos Inc. emphasized that these milestones significantly enhance the company's intellectual property portfolio, supporting clinical progress and potential strategic partnerships [4] - The focus on building a strong IP position is aimed at driving shareholder value and enabling global commercial expansion [4] Company Overview - Vivos Inc. is a clinical-stage medical device company developing RadioGel® for human oncology and IsoPet® for veterinary applications, with IsoPet® already available in certified clinics across the nation [5]

Core Points - The FDA declined approval of Vivos Inc.'s Radiogel® IDE submission after a 30-day review period [1] - The company is focused on addressing the FDA's feedback and plans to have an initial call with the FDA within 10 days [2] - Vivos intends to participate in a pre-submission meeting with the FDA review team in the coming weeks to resubmit the application [2] - Radiogel® has received FDA Breakthrough Device Designation and has shown a strong safety profile and therapeutic ratio [2] Company Actions - Vivos Inc. is committed to pursuing approval for Radiogel® in the US market despite the recent setback [2] - The company is actively engaging with the FDA to resolve the issues raised in the rejection letter [2]